Author:
MAJHI PARESH CHANDRA,NAYAK SUJIT
Abstract
Objectives: Prostate cancer is intensifying globally, including Asian countries also. There are a numerous arguments is still going on in concerning the connection among endogenous testosterone levels and prostate ailments. The present research was performed to recognize the assessment of serum testosterone in identifying the threat and prostate cancer incidences.
Methods: Hundred cases were registered in the research, among that, the cases showing low testosterone value (<250 ng/dL) was considered A Group and cases with normal testosterone value (>250 ng/dL) was considered B Group. All cases those went radical prostatectomy were followed for post-operatively with histopathological analysis and variables, namely, Post-operative Gleason grade, pathological tumor status, pathological node status, surgical margin status, extracapsular extension of tumor, seminal vesicle invasion, and matched among groups. Variables were completed with the Student’s t-test; p<0.05 was considered statistically significant.
Results: Serum testosterone levels as found to be reduced among 74% and regular among 34% prostate cancer cases. Patients in Group A showed greater complete tumor stage, advanced nodal stage, and widespread metastases on scientific assessment associated with Group B.
Conclusion: All the elderly men aged 60 and more should be screened of for serum testosterone levels for timely prostate carcinoma diagnosis and for better prognosis in the management.
Publisher
Innovare Academic Sciences Pvt Ltd
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology
Reference18 articles.
1. Paunikar VM, Barapatre SA. Relationship between endogenous testosterone and prostate carcinoma. J Fam Med Prim Care 2022;11:3735-9. doi: 10.4103/jfmpc.jfmpc_2349_21. PMID 36387691, PMCID PMC9648326
2. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages 20-69;an autopsy study of 249 cases. In vivo. 1994;8:439-43. PMID 7803731
3. Chan JM, Gann PH, Giovannucci EL. Role of diet in prostate cancer development and progression. J Clin Oncol 2005;23:8152-60. doi: 10.1200/JCO.2005.03.1492, PMID 16278466
4. Tayeb MT, Clark C, Haites NE, Sharp L, Murray GI, McLeod HL. CYP3A4 and vitamin D receptor gene polymorphism and risk of prostate cancer in men with benign prostatic hyperplasia. Br J Cancer 2003;88:928-32. doi: 10.1038/sj.bjc.6600825, PMID 12644831
5. Habuchi T, Suzuki T, Sasaki R, Wang L, Sato K, Satoh S, et al. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in Japanese population. Cancer Res 2000;60:305-8. PMID 10667581